A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

SpringerPlus

Table 4 Summary of afatinib pharmacokinetic parameters after multiple oral administrations of afatinib 40 and 30 mg, with letrozole 2.5 mg

Pharmacokinetic parameter (unit)	Afatinib 40 mg			Afatinib 30 mg
Pharmacokinetic parameter (unit)	N	Geometric mean	Geometric CV (%)	N	Geometric mean	Geometric CV (%)
AUC_tau,ss (ng*h/mL)	4	660	41.3	5	579	62.8
C_max,ss (ng/mL)	4	43.8	42.0	5	33.9	79.4
C_{pre,ss, 57} (ng/mL)	5	21.4	42.3	8	15.8	42.1
C_{pre,ss, 85} (ng/mL)	4	16.9	55.7	5	17.3	46.5
t_max,ss (h)^a	4	2	2–4	5	4.00	0.91–7.67

AUC _tau,ss area under the plasma concentration–time curve at steady state over the dosing interval, C _max,ss maximum plasma concentration at steady state, C _{pre,ss, 57} , C _{pre,ss, 85} pre-dose plasma concentration on day 1 of cycles 3 and 4, respectively, CV coefficient of variation, t _max,ss time to maximum plasma concentration at steady state
^aMedian and range